MannKind Corporation Providing AFREZZA™ To Juvenile Diabetes Research Foundation For Artificial Pancreas Project
Links shared publicly online about this topic.
- 922total visits
MannKind Corporation Providing AFREZZA™ To Juvenile Diabetes Research Foundation For Artificial Pancreas Project
View full resource at medicalnewstoday.com
Tags: Diabetes, Insulin, Type 1 Diabetes, Children's Health, Mankind Corp.
Most Recently Shared on August 25, 2010 at 3:00 pm By:
MannKind Corporation Providing AFREZZA™ To Juvenile Diabetes Research Foundation For Artificial Pancreas Project http://mnt.to/3HNs
Also Shared By:
MannKind Provides Regulatory Update - Technology | Centre Daily Times - State College, PA | Penn State, Nittany Lions, weather, news, jobs, homes, apartments, real estate
centredaily.com — “MannKind Corporation (Nasdaq: MNKD) today announced that it was informed by the U.S. Food & Drug Administration (FDA) that due to a potential government shutdown the FDA has decided to cancel an End-of-Review meeting with MannKind that was t... The latest breaking and local news from State College, PA.” View full resource at centredaily.com
Most Recently Shared on April 8, 2011 at 11:25 pm By:
MannKind Provides Regulatory Update http://bit.ly/fm7wJd #insulin #diabetes - not in my son's lungs.
MannKind Corporation Receives Complete Response Letter from the FDA for Afrezza
drugs.com — “Afrezza (insulin human [rDNA origin) is a new drug in development for the treatment of type 1 and type 2 diabetes. Afrezza information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on January 28, 2011 at 5:10 am By:
Drugs and Devices OW OW Health
MannKind Corporation Receives Complete Response Letter from the FDA for Afrezza: VALENCIA, Calif.--(BUSINE... http://bit.ly/fbFRGW #drug
MannKind Corporation Receives Complete Response Letter From The FDA For AFREZZA(R)
medicalnewstoday.com — “MannKind Corporation (Nasdaq: MNKD) announced that it has received a complete response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA&re” View full resource at medicalnewstoday.com
Most Recently Shared on January 21, 2011 at 5:05 pm By:
MannKind Corporation Receives Complete Response Letter From The FDA For AFREZZA(R) http://mnt.to/3Qj3 #diabetes
Investors | Mannkindcorp.com | Press Releases
news.mannkindcorp.com — “Investor information” View full resource at news.mannkindcorp.com
Most Recently Shared on January 19, 2011 at 8:42 pm By:
eyeonfda Pharma and Health Lawyer
MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA(R) - http://ow.ly/3GJiQ
FDA Accepts AFREZZA Complete Response Resubmission And Sets Target Action Date
medicalnewstoday.com — “MannKind Corporation (NASDAQ:MNKD) announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted, MannKind's resubmission of its New Drug Application (NDA) for AFRE” View full resource at medicalnewstoday.com
Most Recently Shared on July 22, 2010 at 12:29 pm By:
FDA Accepts AFREZZA Complete Response Resubmission And Sets Target Action Date: MannKind Corporation (NASDAQ:MNKD)... http://mnt.to/f/3Grh
MannKind reports AFREZZA is both effective and safe. IDEXX jumps on strong earnings - BioMedReports.com
biomedreports.com — “Below is a list of the companies that made news in the healthcare sector on Friday, April 24, 2010. MannKind Corporation (Nasdaq:MNKD) today released data from two separate Phase III trials that indicate that its experimental inhaled insulin device,” View full resource at biomedreports.com
Most Recently Shared on April 24, 2010 at 6:45 pm By:
Afrezza "without causing meaningful changes in lung function." http://bit.ly/9Nkjnb No interest in inhalable insulin for diabetes in my son!
FDA Requests Additional Information Regarding AFREZZA in Complete Response Letter to MannKind Corporation - News, Search Jobs, Events
biospace.com — “FDA Requests Additional Information Regarding AFREZZA in Complete Response Letter to MannKind Corporation - News, Search Jobs, Events” View full resource at biospace.com
Most Recently Shared on March 15, 2010 at 2:13 pm By:
Scott Strumello Patient Expert
FDA Requests Additional Information Regarding AFREZZA in Complete Response Letter to MannKind Corp. http://bit.ly/bVshDz
MannKind Corporation Updates Status of New Drug Application; FDA to Delay Review of Insulin Device - News, Search Jobs, Events
biospace.com — “MannKind Corporation Updates Status of New Drug Application; FDA to Delay Review of Insulin Device - News, Search Jobs, Events” View full resource at biospace.com
Most Recently Shared on January 11, 2010 at 3:46 pm By:
Scott Strumello Patient Expert
"MannKind Corp. Updates Status of NDA for Afrezza; FDA to Delay Review of Insulin Device": http://bit.ly/5i0FnF
Advertisement
Scott Strumello
@sstrumello
"MannKind Corp. Updates Status of NDA for Afrezza; FDA to Delay Review of Insulin Device": http://bit.ly/5i0FnF
1 year ago...